RAMESH PARCHURI: Open Payments
NPI 1437224300 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,238 in 64 payments from 17 companies in 2025. Trend: 2023 $1,309 · 2024 $974 · 2025 $1,238
Food & beverage: $1,238
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 26 | $358 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $155 |
| E.R. Squibb & Sons, L.L.C. | 5 | $119 |
| AstraZeneca Pharmaceuticals LP | 5 | $100 |
| Verona Pharma, Inc. | 3 | $87 |
| ABBVIE INC. | 3 | $69 |
| Astellas Pharma US Inc | 2 | $50 |
| Lilly USA, LLC | 2 | $48 |
| Vanda Pharmaceuticals Inc. | 2 | $44 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $38 |
Products named: TRELEGY ELLIPTA, JARDIANCE, COBENFY, Ohtuvayre, VRAYLAR, Veozah, FANAPT, FARXIGA.
Industry payments across PA — which companies pay providers there.
